$HLTHQ
Cue Health Inc. Stock $hlthq

$hlthq Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162894523000094 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$9.896M	$24.77M
YoY Change	-88.72%	-86.2%
Cost Of Revenue	$29.35M	$39.82M
YoY Change	-71.2%	-54.07%
Gross Profit	-$19.45M	-$15.06M
YoY Change	36.99%	-116.24%
Gross Profit Margin	-196.54%	-60.8%
Selling, General & Admin	$22.76M	$28.19M
YoY Change	-46.29%	-53.85%
% of Gross Profit
Research & Development	$36.54M	$44.73M
YoY Change	-16.96%	55.39%
% of Gross Profit
Depreciation & Amortization	$10.60M	$12.06M
YoY Change	3.92%	13.75%
% of Gross Profit
Operating Expenses	$59.30M	$72.92M
YoY Change	-31.35%	-18.86%
Operating Profit	-$85.39M	-$95.85M
YoY Change	-16.66%	-3465.52%
Interest Expense	-$291.0K	-$220.0K
YoY Change	1718.75%	331.37%
% of Operating Profit
Other Income/Expense, Net	$1.820M	$1.872M
YoY Change	4132.56%	31100.0%
Pretax Income	-$83.86M	-$94.20M
YoY Change	-18.13%	-3460.61%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$83.86M	-$94.20M
YoY Change	-15.33%	-3460.61%
Net Earnings / Revenue	-847.45%	-380.37%
Basic Earnings Per Share	-$0.55	-$0.62
Diluted Earnings Per Share	-$0.55	-$0.62
COMMON SHARES
Basic Shares Outstanding	151.6M shares	151.4M shares
Diluted Shares Outstanding	151.9M shares	151.1M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.6M	$178.2M
YoY Change	-64.6%	-58.21%
Cash & Equivalents	$128.6M	$178.2M
Short-Term Investments
Other Short-Term Assets	$3.326M	$4.574M
YoY Change	-72.71%	-53.36%
Inventory	$68.37M	$82.01M
Prepaid Expenses	$9.318M	$11.62M
Receivables	$1.707M	$9.799M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$212.1M	$287.0M
YoY Change	-65.8%	-59.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$258.2M	$268.7M
YoY Change	-6.48%	0.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.802M	$5.333M
YoY Change	-44.91%	-6.09%
Total Long-Term Assets	$311.8M	$321.6M
YoY Change	6.07%	13.88%
TOTAL ASSETS
Total Short-Term Assets	$212.1M	$287.0M
Total Long-Term Assets	$311.8M	$321.6M
Total Assets	$523.9M	$608.6M
YoY Change	-42.69%	-38.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.21M	$16.64M
YoY Change	-70.77%	-65.92%
Accrued Expenses	$43.60M	$47.91M
YoY Change	-47.79%	1.07%
Deferred Revenue	$468.0K	$754.0K
YoY Change	-99.45%	-99.11%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.756M	$2.148M
YoY Change	-32.59%	-18.02%
Total Short-Term Liabilities	$57.03M	$67.46M
YoY Change	-72.85%	-64.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$417.0K
YoY Change	-100.0%	-84.13%
Other Long-Term Liabilities	$1.997M	$1.997M
YoY Change	-59.6%	-68.58%
Total Long-Term Liabilities	$1.997M	$1.997M
YoY Change	-59.6%	-68.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.03M	$67.46M
Total Long-Term Liabilities	$1.997M	$1.997M
Total Liabilities	$100.7M	$112.7M
YoY Change	-63.21%	-56.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.1M	-$312.3M
YoY Change	229.36%	1371.94%
Common Stock	$2.000K	$2.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$423.2M	$495.9M
YoY Change
Total Liabilities & Shareholders Equity	$523.9M	$608.6M
YoY Change	-42.69%	-38.14%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$83.86M	-$94.20M
YoY Change	-15.33%	-3460.61%
Depreciation, Depletion And Amortization	$10.60M	$12.06M
YoY Change	3.92%	13.75%
Cash From Operating Activities	-$42.66M	-$53.88M
YoY Change	-17.69%	-270.94%
INVESTING ACTIVITIES
Capital Expenditures	$5.990M	$3.906M
YoY Change	-129.04%	-69.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$5.990M	-$8.318M
YoY Change	-70.96%	-40.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-996.0K	-$1.128M
YoY Change	-70.6%	29.21%
NET CHANGE
Cash From Operating Activities	-42.66M	-$53.88M
Cash From Investing Activities	-5.990M	-$8.318M
Cash From Financing Activities	-996.0K	-$1.128M
Net Change In Cash	-49.65M	-$63.33M
YoY Change	-34.54%	-481.66%
FREE CASH FLOW
Cash From Operating Activities	-$42.66M	-$53.88M
Capital Expenditures	$5.990M	$3.906M
Free Cash Flow	-$48.65M	-$57.79M
YoY Change	55.91%	-408.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001628945
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40590
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Cue Health Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1562193
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4980 Carroll Canyon Rd.
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	412-8151
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	HLTH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151618769	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178201000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	241530000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	800000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	800000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9799000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18751000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	82006000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	82210000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11617000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	15728000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4574000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12134000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	286997000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	371153000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	27718000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25436000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	184197000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	189275000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84542000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85321000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19774000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16867000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5333000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6528000	usd
CY2023Q1	us-gaap	Assets Assets	608561000	usd
CY2022Q4	us-gaap	Assets Assets	694580000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16644000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7150000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	40173000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	52378000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	754000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1566000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7739000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7739000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2148000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2362000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	67458000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71195000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42826000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44045000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	417000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	849000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1997000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1997000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	112698000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	118086000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151567650	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151567650	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150406014	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150406014	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	808133000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	794567000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-312272000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218074000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	495863000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	576494000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	608561000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	694580000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24765000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179410000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11248000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	34168000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44733000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28787000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16938000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26910000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	7873000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	120615000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	176562000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-95850000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2848000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-220000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-51000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1872000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94198000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2803000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-94198000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2803000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151083716	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146526370	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151083716	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153036804	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	576494000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	473080	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	924000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14407000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	12000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-94198000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	495863000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	706750000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	270000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	720000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16035000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2803000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	725138000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-94198000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2803000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12064000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10606000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	312000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-229000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14407000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16035000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2278000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1996000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	24000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	51000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	79000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	65000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-8640000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-28988000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2078000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	44179000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11659000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1618000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1116000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1876000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4656000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18254000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-812000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2464000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2718000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5075000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53883000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31521000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3906000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12782000	usd
CY2023Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	4412000	usd
CY2022Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1273000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8318000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14055000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	270000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	924000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	720000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	370000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	273000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	670000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	696000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1128000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-873000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-63329000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16593000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242330000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423710000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179001000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	440303000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178201000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	426465000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	800000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	13838000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179001000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	440303000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2611000	usd
CY2023Q1	hlth	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	0	usd
CY2022Q1	hlth	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	50000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2548000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9235000	usd
CY2023Q1	hlth	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	0	usd
CY2022Q1	hlth	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	897000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying unaudited interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, net accounts receivable, equity-based compensation expense, product warranty reserve, the usage and recoverability of its inventories and long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	12000000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	300000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1566000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	92448000	usd
CY2023Q1	hlth	Contract With Customer Liability Unearned Revenue From Cash Received During The Period ContractWithCustomerLiabilityUnearnedRevenueFromCashReceivedDuringThePeriod	556000	usd
CY2022Q1	hlth	Contract With Customer Liability Unearned Revenue From Cash Received During The Period ContractWithCustomerLiabilityUnearnedRevenueFromCashReceivedDuringThePeriod	2464000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1368000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	754000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	94912000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	27718000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25436000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	80939000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	80968000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	12647000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14305000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	45061000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	37867000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	28923000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	25494000	usd
CY2023Q1	hlth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	109724000	usd
CY2022Q4	hlth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	107646000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	82006000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	82210000	usd
CY2023Q1	hlth	Prepaid Expense Excluding Prepaid Inventory Current PrepaidExpenseExcludingPrepaidInventoryCurrent	7892000	usd
CY2022Q4	hlth	Prepaid Expense Excluding Prepaid Inventory Current PrepaidExpenseExcludingPrepaidInventoryCurrent	11523000	usd
CY2023Q1	hlth	Prepaid Inventory Current PrepaidInventoryCurrent	3725000	usd
CY2022Q4	hlth	Prepaid Inventory Current PrepaidInventoryCurrent	4205000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11617000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	15728000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	277710000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	272230000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	93513000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	82955000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	184197000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	189275000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	10600000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	10000000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6600000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	7300000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	18658000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	19052000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	7229000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	5724000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	11429000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	13328000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19774000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16867000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84542000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85321000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6624000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	7264000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7739000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7739000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2148000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2362000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42826000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44045000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	417000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	849000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2988000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2762000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	640000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	639000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	24000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	51000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	3652000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	3452000	usd
CY2023Q1	hlth	Accrued Liabilities Purchases Current AccruedLiabilitiesPurchasesCurrent	2517000	usd
CY2022Q4	hlth	Accrued Liabilities Purchases Current AccruedLiabilitiesPurchasesCurrent	4488000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14211000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26350000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7894000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5553000	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	385000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1361000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	6584000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	6660000	usd
CY2023Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	365000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2023Q1	hlth	Accrued Purchase Commitment Loss Current AccruedPurchaseCommitmentLossCurrent	8217000	usd
CY2022Q4	hlth	Accrued Purchase Commitment Loss Current AccruedPurchaseCommitmentLossCurrent	7966000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	40173000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	52378000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7102853	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3473387	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.15
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	142141	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.70
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	754996	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.37
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	5500	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.61
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9673603	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.97
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5587957	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.42
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9673603	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.97
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-94198000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2803000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151083716	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146526370	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151083716	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153036804	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32838485	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12446972	shares
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	hlth	Standard Product Warranty Term StandardProductWarrantyTerm	P12M
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	6660000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3322000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	3398000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	6584000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	7873000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	7247000	usd
CY2023Q1	us-gaap	Restructuring Reserve Translation And Other Adjustment RestructuringReserveTranslationAndOtherAdjustment	-261000	usd
CY2023Q1	us-gaap	Restructuring Reserve RestructuringReserve	365000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	800000	usd

Files In Submission

Name	View Source	Status
hlth-20230331_lab.xml	Edgar Link	unprocessable
hlth-20230331_cal.xml	Edgar Link	unprocessable
0001628945-23-000094-index-headers.html	Edgar Link	pending
0001628945-23-000094-index.html	Edgar Link	pending
0001628945-23-000094.txt	Edgar Link	pending
0001628945-23-000094-xbrl.zip	Edgar Link	pending
exhibit31103312310-q.htm	Edgar Link	pending
exhibit31203312310-q.htm	Edgar Link	pending
exhibit32103312310-q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hlth-20230331.htm	Edgar Link	pending
hlth-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
hlth-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hlth-20230331_pre.xml	Edgar Link	unprocessable
hlth-20230331_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HLTHQ
Cue Health Inc. Stock $hlthq

2023 Q2 Form 10-Q Financial Statement

#000162894523000094 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLTHQ Cue Health Inc. Stock $hlthq

2023 Q2 Form 10-Q Financial Statement

#000162894523000094 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLTHQ
Cue Health Inc. Stock $hlthq